DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

Information source: Medical Centre of Postgraduate Education, Poland
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hip Osteoarthritis; Blood Loss

Intervention: Enoxaparin (Drug); rivaroxaban (Drug); dabigatran (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Medical Centre of Postgraduate Education, Poland

Official(s) and/or principal investigator(s):
Marcin K Wasko, M.D., Ph.D., Principal Investigator, Affiliation: The Medical Centre of Postgraduate Education, Department of Orthopaedics and Inflammatory Disorders of Locomotor System

Overall contact:
Marcin K Wasko, M.D., Ph.D., Phone: +48227794031, Ext: 384, Email: m.wasko@cmkp.edu.pl

Summary

The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).

Clinical Details

Official title: Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Primary outcome: Total blood loss by the 3rd postoperative day

Secondary outcome:

Drop in the haemoglobin value between 3rd day postop and preoperative

Wound healing disturbances according to the definition of Centers for Disease Control and Prevention

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- primary, end-stage hip osteoarthritis requiring total hip arthroplasty

Exclusion Criteria:

- inflammatory arthropathies

- liver disorders

- neoplastic conditions

- clotting disorders

Locations and Contacts

Marcin K Wasko, M.D., Ph.D., Phone: +48227794031, Ext: 384, Email: m.wasko@cmkp.edu.pl

Prof. A. Gruca Teaching Hospital, The Medical Centre of Postgraduate Education, Otwock, Woj. Mazowieckie 05-400, Poland; Recruiting
Marcin K Wasko, M.D., Ph.D., Principal Investigator
Additional Information

Starting date: July 2012
Last updated: March 13, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017